Navigation Links
UCSF, Sanofi Collaborate to Find New Diabetes Cures

SAN FRANCISCO, Jan. 10, 2012 /PRNewswire/ -- The University of California, San Francisco (UCSF) has signed an alliance with international pharmaceutical company Sanofi (EURONEXT: SAN and NYSE: SNY) to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

The $3.1 million collaboration will bring together scientists in three UCSF labs with deep understanding of the biology of beta cells – insulin-producing cells that are destroyed in type 1 diabetes and often produce too little insulin in type 2 – with Sanofi researchers who are experienced in developing potential drug candidates into actual therapies.

"This is a true partnership between scientists with very different strengths," said Matthias Hebrok, PhD, director of the UCSF Diabetes Center. "UCSF is known for its deep understanding of the underlying biology of diabetes, while Sanofi has great expertise in screening compounds, identifying which molecules have potential, and moving them along to develop a new drug. Such an endeavor is almost impossible to accomplish in a single academic laboratory. Thus, both partners profit from the expertise of the other group."

The alliance is the university's third collaboration with Sanofi, alongside brain trauma and oncology research launched last year, since the two signed a master agreement in January 2011 to work together in translating academic science into potential new therapies. Master agreements lay out the fundamental terms of research collaborations, align with the university's academic mission including broad publication rights, and form part of a core strategy for the UCSF Office of Innovation, Technology and Alliances to expedite that "bench-to-bedside" research.

This also is the first collaboration of its kind for the UCSF Diabetes Center, extending beyond simpler, funded-research agreements to create a two-way partnership in which scientists on both sides contribute technology and expertise to identify drug targets and test their potential.

"Sanofi is pleased to collaborate with the Diabetes Center at UCSF to combine expertise in employing new technologies for the development of innovative diabetes therapies," said Pierre Chancel, Senior Vice President, Diabetes Division, Sanofi. "The potential resulting drug discovery projects will supplement our integrated solutions model for diabetes management and help Sanofi continue to deliver best-in-class solutions to people living with diabetes."

Together, the team will assess and validate potential drug targets from a UCSF library of roughly 100,000 small interference RNAs (siRNA) – molecules that play a crucial role in turning on and off genes, including the gene that produces insulin. They also will identify Sanofi compounds that might be effective in regulating those molecules, study the impact those compounds have on UCSF laboratory models of diabetes and assess their therapeutic potential.

In the United States alone, 46 percent of adults had diabetes or pre-diabetes in 2010, according to the Centers for Disease Control & Prevention (CDC), which projects a full third of Americans will have the disease in 2050. It is the leading cause of blindness and kidney failure, a major cause of heart disease and stroke, and the seventh-highest cause of death. Diabetes care costs $116 billion each year in the United States alone, according to the CDC, with an additional $58 billion toll in lost productivity and early mortality.

The initial project, intended as a pilot for broader joint research into diabetes, will operate under the oversight of an expert panel from UCSF and Sanofi, and focus on beta cells, drawing on the expertise of three renowned UCSF Diabetes Center researchers and their laboratories:

  • Michael McManus, PhD, a molecular biologist and expert in microRNA and the way genes are expressed, or turned into genetic products such as insulin and other proteins;
  • Hebrok, an expert on beta-cell biology and development who holds the UCSF Hurlbut-Johnson Distinguished Professorship in Diabetes Research; and
  • Michael German, MD, an expert on beta-cell function and how cells transcribe DNA into RNA to create proteins, who is clinical director of the Diabetes Center and holds the Justine K. Schreyer Endowed Chair in Diabetes Research.

UCSF and its Diabetes Center have a long history of breakthroughs in diabetes and beta-cell research, spanning from the first cloning of the insulin gene to the first clinical studies blocking autoimmune destruction of beta cells. Diabetes Center researchers and their affiliated members are renowned experts in their respective fields: Immunology, b-cell Biology, Islet & Pancreas Transplantation, and RNAi/microRNAs.

About the University of California, San Francisco – UCSF

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such 3/3 as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

Follow UCSF | | |

Amy Pyle, Executive Director, News
Source: Kristen Bole (415) 502-6397 (NEWS)

Sanofi US
Susan Brooks, (908) 981-6566

SOURCE Sanofi and University of California, San Francisco
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
2. Sanofi Pasteur Launches Nationwide Education Campaign to Help Parents Make Informed Decisions about Immunization
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sanofi Tops Pfizer as Number One for Global Pharma Sales
5. Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population
6. Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine
7. Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy
8. Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
9. New Senior Executives Appointed at Sanofi:
10. Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season
11. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Aliso Viejo, CA (PRWEB) , ... November 26, ... ... X users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. ... custom style options. These classically-influenced trailer titles work with any font, giving users ...
Breaking Medicine News(10 mins):